A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 600.18% and ...

Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...

Eli Lilly (LLY) closed the most recent trading day at $909.32, moving -1.65% from the previous trading session.

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity ...